We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

110 hedge funds and large institutions have $136M invested in Insys Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

44% more capital invested

Capital invested by funds: $94.2M → $136M (+$41.3M)

17% more call options, than puts

Call options by funds: $5.49M | Put options by funds: $4.68M

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

7% more funds holding

Funds holding: 103 → 110 (+7)

Holders
110
Holders Change
+7
Holders Change %
+6.8%
% of All Funds
2.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
28
Reduced
25
Closed
11
Calls
$5.49M
Puts
$4.68M
Net Calls
+$806K
Net Calls Change
+$3.44M

Top Buyers

Rank Fund Capital Flow
1
Norges Bank
Norges Bank
Norway
+$1.75M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$955K
4
Millennium Management
Millennium Management
New York
+$949K
5
PAM
Panagora Asset Management
Massachusetts
+$803K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$3.85M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$652K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$477K
4
Barclays
Barclays
United Kingdom
-$322K
5
VF
Virtu Financial
New York
-$253K
Name Holding Trade Value Shares
Change 		Change in
Stake
CLOS
76
Compagnie Lombard Odier SCmA
Switzerland
$10K -$16K -2,000 -67%
SWP
77
Stratos Wealth Partners
Ohio
$9K +$6.88K +863 New
AA
78
AlphaMark Advisors
Kentucky
$8K – – –
Federated Hermes
79
Federated Hermes
Pennsylvania
$8K – – –
SIS
80
Sound Income Strategies
Florida
$6K – – –
PCM
81
Prelude Capital Management
New York
$5K -$1.08K -136 -22%
Walleye Trading
82
Walleye Trading
New York
$5K +$3.78K +474 New
Daiwa Securities Group
83
Daiwa Securities Group
Japan
$4K – – –
GSC
84
G&S Capital
Colorado
$4K – – –
IA
85
IFP Advisors
Florida
$4K – – –
RIA
86
RPG Investment Advisory
California
$4K – – –
VRM
87
Vectors Research Management
New York
$4K +$4.03K +505 New
Simplex Trading
88
Simplex Trading
Illinois
$3K -$16.5K -2,068 -87%
NSIM
89
North Star Investment Management
Illinois
$3K – – –
SIAP
90
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$3K – – –
MAM
91
Meeder Asset Management
Ohio
$3K +$471 +59 +21%
NCM
92
New Capital Management
Texas
$3K +$2.36K +296 New
BWA
93
BDO Wealth Advisors
Florida
$3K +$2.39K +300 New
TRCT
94
Tower Research Capital (TRC)
New York
$2K -$143K -17,878 -99%
ML
95
McAdam LLC
Pennsylvania
$2K – – –
Northwestern Mutual Wealth Management
96
Northwestern Mutual Wealth Management
Wisconsin
$2K – – –
WA
97
WealthTrust-Arizona
Arizona
$2K – – –
NFG
98
Next Financial Group
Texas
$2K +$1.59K +200 New
FDCDDQ
99
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.21K – – –
AWM
100
Avior Wealth Management
Nebraska
$1K -$5.18K -650 -93%
1 2 3
4
5

INSY Hedge Fund Activity: Q3 2018 in Review

110 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2018, worth a combined $136M — up 44% from $94.2M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new INSY positions and 11 closed out — a net gain of 7 holders — while 28 added to existing stakes and 25 trimmed.

The largest buyer was Norges Bank, adding an estimated $1.75M. The largest seller was OrbiMed, cutting an estimated $3.85M.

  • 110 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2018, up from 103 in Q2 2018.
  • Funds reported $136M of Insys Therapeutics, Inc. stock for Q3 2018, up 44% quarter-over-quarter.
  • 18 funds opened new Insys Therapeutics, Inc. positions in Q3 2018 and 11 closed out, a net change of +7 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q3 2018 was Norges Bank, an estimated $1.75M added.
  • The largest Insys Therapeutics, Inc. seller in Q3 2018 was OrbiMed, an estimated $3.85M sold.

Based on aggregated 13F filings for Q3 2018.